Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

A new survey found the COVID-19 pandemic changed many Americans view of obesity and caused others to consider new weight-loss methods due to their...

In this interview, Siperstein explained some of the biggest takeaways from her conference presentation on advances in microneedling techniques, including radiofrequency...

  • 1639809445117980673 Profile photo of Madelyn

    ICYMI: In this #AAD23 interview, Dr. Robyn Siperstein explained some of the biggest takeaways from her conference presentation on advances in #microneedling techniques, including radiofrequency specifically: https://t.co/y8nSA7dY21 - view on twitter

A phase 2 trial comparing once weekly basal insulin Fc against once daily insulin degludec, results of the study will help provide the basis...

  • 1639764161457451010 Profile photo of Madelyn

    New research from a phase 2 trial suggests once-weekly basal insulin Fc achieved similar glycemic control as once-daily insulin degludec in patients with #Type2Diabetes: https://t.co/N6YjjcpB4X - view on twitter

Statistical analysis showed no differences between each pairwise comparison of the bevacizumab biosimilars, MB02-SP and MB02-DM, and the reference...

Upadacitinib, a selective and reversible Janus kinase (JAK) inhibitor, may be a promising treatment option for patients with systemic lupus...

Industry payments to cardiologists remained highly prevalent in each year of study, but the research showed significant declines in the total value of payments...

  • 1639673609605066752 Profile photo of Madelyn

    Cardiologists in the United States received 5.5 million industry payments totaling $1.1 billion from 2014 to 2019, according to new study results. Read more: https://t.co/mDOQs0peqC #cardiology - view on twitter

The approval was based on positive results from the phase I pharmacokinetics bridging study, which showed comparable PK and similar safety and immunogenicity of...

  • 1639643441515888642 Profile photo of Madelyn

    ICYMI: The FDA approval was based on positive results from the phase I pharmacokinetics bridging study, which showed comparable PK and similar safety and immunogenicity of #biosimilar adalimumab 50 mg/mL and adalimumab high-concentration formulation. https://t.co/UBfYCpBagR - view on twitter

New data highlighted racial and ethnic differences between patients with Merkel cell carcinoma, indicating that rates for survival were roughly similar but other distinctions...

  • 1639628306634113024 Profile photo of Madelyn

    New data highlighted racial & ethnic differences between Merkel cell carcinoma patients, indicating that rates for survival were similar but other distinctions remained. Check out the story here: https://t.co/7la2G7yPKm - view on twitter

In a recent phase 2 trial, abatacept failed to significantly reduce progression to diabetes or abnormal glucose tolerance among a cohort of stage 1...

No significant budget increase was observed in patients with non-radiographic axial spondyloarthritis (nr-axSpA) receiving...